Top Page | English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 31 July 2015, 12:00 HKT/SGT
Share:
    

Source: Eisai
Continuation of "Policy for Protection of The Company's Corporate Value and Common Interests of Shareholders (Shareholder Rights Plan)"

TOKYO, July 31, 2015 - (JCN Newswire) - The Board of Directors of Eisai Co., Ltd. (Chair: Kiyochika Ota) passed a resolution for the continuation of the "Policy for Protection of the Company's Corporate Value and Common Interests of Shareholders" ("the Policy"), which was proposed by the Independent Committee of Outside Directors (Chair: Osamu Suzuki, "ICOD") at its meeting held today.

The proposal to continue the Policy was deliberated at an ICOD meeting of all seven outside directors elected at the Ordinary General Meeting of Shareholders held on June 19, 2015. The ICOD determined that it was appropriate to propose the continuation of the Policy in its present form to the Board of Directors since it incorporates the following provisions:

1. The Policy precludes arbitrary actions on the part of the management
2. The continuation, amendment, or abandonment of the Policy shall be deliberated each year
3. Shareholders' opinions concerning the Policy may be reflected through the election of directors at the Ordinary General Meeting of Shareholders

The Policy was initially adopted after being proposed by the ICOD at an Eisai Board of Directors meeting held in February 2006. After subsequent changes were made to certain policy provisions through an Eisai Board of Directors meeting in August 2011, it was determined that the Policy is to remain in effect until June 30, 2016. The continuation, amendment, or abandonment of the Policy is deliberated by the newly appointed ICOD following the Ordinary General Meeting of Shareholders each year.

Further information on the Policy is provided in the "Corporate Governance" section of the Eisai Global website (http://www.eisai.com/company/ecgpolicy20150731.pdf).

At present, Eisai has not received any specific proposals concerning the large-scale purchase of the company shares.


Contact:
Public Relations Department,
Eisai Co., Ltd.
+81-3-3817-5120



Topic: Press release summary
Source: Eisai

Sectors: BioTech
http://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.



Eisai
Dec 11, 2025 18:41 HKT/SGT
Eisai Rated "A", the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year
Dec 9, 2025 17:51 HKT/SGT
"LEQEMBI(R)" (lecanemab) for the Treatment of Early Alzheimer's Disease Included in China's Commercial Insurance Innovative Drug List
Dec 4, 2025 17:36 HKT/SGT
Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI(R) (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at CTAD 2025
Dec 3, 2025 17:19 HKT/SGT
New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI(R) (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF
Dec 2, 2025 23:01 HKT/SGT
Eisai Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Nov 28, 2025 22:00 HKT/SGT
Eisai Submits New Drug Application for Subcutaneous Formulation of "LEQEMBI(R)" for the Treatment of Early Alzheimer's Disease in Japan
Nov 26, 2025 18:42 HKT/SGT
Eisai Completes Rolling Submission to US FDA for LEQEMBI(R) IQLIK(TM) (lecanemabirmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer's Disease Under Fast Track Status
Nov 17, 2025 21:08 HKT/SGT
"LEQEMBI(R)" (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
Oct 30, 2025 13:43 HKT/SGT
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 28, 2025 23:30 HKT/SGT
Merck & Co., Inc. and Eisai Announce WELIREG(R) (belzutifan) Plus LENVIMA(R) (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
More news >>
 News Alerts
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Privacy Policy | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575

Connect With us: